Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran for Hereditary Angioedema
Fortune Minerals Announces David Massola Has Rejoined the Company as Vice President Business Development
NevGold Releases Significant Oxide Gold-Antimony Results: 11.41 g/t AuEq Over 6.1 Meters Within 2.19 g/t AuEq Over 56.4 Meters at the Limousine Butte Project, Nevada
